Injection of the TRPV1 antagonists A-889425 and JNJ-17203212 systemically reduced pain behaviors in the monoiodoacetate (MIA) model of arthritis pain, and also reduced the firing of peripheral A- and C-fiber joint afferents, as well as the firing of nociceptive and wide dynamic range neurons in the dorsal horn of the spinal cord in response to peripheral stimuli in these animals [48,49]. Here, TRPV1 is linked to arthritic joint disease.